Introduction
Low folate status -originally identified as a cause of macrocytotic anemia, especially in pregnancy -is increasingly recognized as an important marker for disease in a variety of conditions, including some varieties of cancer. Folate deficiency is associated with elevated levels of homocysteine, and attendant cerebrovascular disease, neurological disease, and mood disorders. There is a higher prevalence of folate deficiency in elderly people -some evidence suggests that approximately 30% of healthy older people may have insufficient folate [1] and folate insufficiency can potentially affect over 80% of psychogeriatric patients [2] . Moreover, some research suggests that even with normal serum levels of folate, cerebrospinal fluid (CSF) levels may be inadequate in people with folate transport impairments [3] and with age [4] . The elderly are at particular risk for folate deficiency due to decreased absorption of B vitamins, dietary inadequacies, and drug interactions. Although severe folate deficiency is rare in the US, subclinical deficiencies may prove to have significant consequences in health status across the life span. People with 'low-normal' levels of folate may be at risk for some of the negative consequences of folate deficiency [5, 6] . Importantly, such marginal deficiencies and related negative sequelae may be reversible with dietary supplementation.
Folate, most richly found in liver, leafy greens, citrus fruits, and yeast extracts, is an essential nutrient and functions as a cofactor in many biochemical processes, most notably in one-carbon metabolism [7] . Folic acid, a synthetic analog of folate, is now added to bread and cereal products in the US as part of a large-scale fortification practice that began in 1998. Folic acid fortification was undertaken chiefly to prevent the development of neural tube defects in infants. However, folic acid fortification may have further implications for public health [8, 9] .
One of the important metabolic roles of folate is in the mediation of homocysteine levels. Homocysteine is widely associated as a risk factor for atherosclerosis, cerebrovascular disease, and dementia. It is metabolized from the essential amino acid methionine. Folate acts as a methyl donor in the remethylation of homocysteine to methionine ( Fig. 1 ). Lower levels of folate are thus implicated in increased levels of homocysteine. Vitamin B12 and folate are closely linked in the methylation process, such that a B12 deficiency can lead to a secondary folate deficiency through a decrease in the retention of folate [10] . It is proposed that low levels of B12 are linked with peripheral neuropathy and subacute combined degeneration of the spinal cord, whereas folate may have more of a role in cognition and mood, perhaps through effects on serotonin, dopamine, and noradrenergic systems [6,11 . ].
Folate and mood
Depression in the elderly is of significant concern, not only as a condition affecting quality of life in its own right, but also because depression can masquerade as dementia and negatively influence cognition -in the extreme it is described as depressive pseudodementia [5] . Moreover, depression may precede later dementia [13] . Low levels of serum folate are common in clinically depressed patients [6, 14, 15] and, conversely, depression is frequently present in folate-deficient people [16] . Morris and colleagues [17 . . ] recently examined folate status in a broad cross-section of the US population aged 15-39 and related folate levels to lifetime depressive episodes. Lower levels of red blood cell (RBC) folate were seen in people categorized as having major depression or dysthymia relative to people who had never been depressed. Serum levels of folate were significantly lower in people who had experienced major depression relative to those who had never been depressed. Serum folate levels were not significantly different between people with dysthymia relative to those who had never been depressed, suggesting that RBC folate assays are more sensitive to determining inadequacies that could influence mood. Finally, folate deficiency was more pronounced in those people who had recent depressive episodes, and the authors suggest that folate supplementation may be of benefit in the year following such episodes. Tolmunen and colleagues [18 . ] also found a strong link between folate intakes and current depressive symptoms in middle-aged Finnish men. In the Finnish study, as in other reports, men with depressive symptoms also consumed fewer calories, consumed more alcohol and reported poor appetite. Thus, men with depressive symptoms were consuming less folate in conjunction with a lower overall energy intake. Therefore, it is not possible from this study to determine whether folate deficiency in this population is a predecessor or successor to depression -a common concern in studies comparing dietary intakes concurrently with physiological or psychological variables.
Several older studies show that folate and depression are linked in older people (see [19] for a review). Unlike the studies described above, however, which looked at younger people, several current reports [5, 20] have not conclusively shown a relationship between folate status and depression in free-living elderly. For example, Penninx and colleagues [20] examined serum levels of vitamin B12, folate, homocysteine, and methylmalonic acid in community-dwelling elderly women with physical disability. They found an inverse relationship between B12 status and homocysteine and methylmalonic acid levels, and a strong relationship between B12 levels and severe depression -but not for mild depression. With respect to folate, however, they found no relationship between serum levels and depression. Moreover, the prevalence of folate deficiency in the freeliving population studied was lower than in depressed inpatient populations. Lindeman and colleagues [5] also studied the relationship between serum folate and vitamin B12 levels as well as vitamin C levels and mood and cognition in elderly Hispanics and non-Hispanic whites. Overall, males and Hispanics had lower levels of the three vitamins studied than females and non-Hispanic whites. Although they did not find a relationship between folate and depression in the present study, they did find a relationship between folate and cognition, which will be discussed in a later section. Serum folate levels were not associated with depression in a subsection of the Rotterdam study, but B12 levels were [21] . Finally, Bryan and colleagues [22] did not show a relationship between folate intakes, as measured through food frequency questionnaires, and mood.
Some data show that folate may potentiate the effects of antidepressants in the treatment of depression [23] and that people with low levels of folate are less responsive to the therapeutic effects of antidepressant medications [14, 15] . Alpert and colleagues [11 . ] compared baseline RBC folate levels with antidepressant treatment outcome in depression in older people. They showed that folate status at the beginning of the trial was strongly linked with improvements following treatment with sertraline, a selective serotonin reuptake inhibitor, but not with nortriptyline, which exerts its effects via the noradrenergic system. These findings are consistent with the hypothesis that reductions in S-adenosylmethionine resulting from folate deficiency may lead to lower levels of serotonin in depressed people, and thus that mood may be, in some circumstances, nutritionally mediated [14, 24] .
Despite the limited evidence for folate deficiency in the etiology of depression in free-living elders, the relationships among folate, cognition, and depression should not be ignored. Moreover, the findings with respect to folate status and antidepressant efficacy suggest that there is a role for folate in depression. It is possible that the effects of folate and homocysteine levels on cognition overpower the effects of folate on depression. In younger people folate and depression are strongly linked [17 . . ], but it may be that younger people also show smaller decrements in cognition as a function of folate. More research on low folate and cognition in different age groups of otherwise healthy people would substantiate this supposition. [28,29 . ,30,31] . While it has yet to be determined whether homocysteine is causative in cognitive decline, the relationship between folate and homocysteine and cognition has been intensively studied. In keeping with the scope of this review, reports specifically addressing folate and cognition will be discussed. More abundant reports of homocysteine and cognitive impairment, while possibly reflective of folate and B vitamin status, will be noted where folate and B vitamin associations are explicitly reported.
Folate and cognition
Previous studies show an association between B vitamin and folate status and neurocognitive functioning in older people (see [12] for a review). There is much about this relationship that remains unclear. In nondemented populations, homocysteine and vitamin status have been compared with cognitive performance on a variety of tasks. Miller and colleagues [32] show that RBC folate levels are predictive of homocysteine levels. Elevated homocysteine levels, in turn, are associated with poorer performance on several cognitive tasks. In this study, however, there was no clear relationship between folate status and cognitive performance. Teunissen and colleagues [33] found that serum levels of homocysteine were negatively correlated with verbal learning and memory at baseline testing only. Elevated homocysteine was associated with poorer functioning on several cognitive tasks looking at immediate recall, attention and performance during a 6-year follow-up period. At baseline, higher serum folate levels were associated with better performance on a delayed recall task, but no other associations were found either for other cognitive tasks or at later time points. Morris and coworkers [25] reported similar findings with respect to folate and recall. Folate status was positively correlated with recall performance. Moreover, elevated levels of homocysteine were associated with poor recall. When looking at folate and homocysteine levels, low folate levels in combination with higher levels of homocysteine (above the 80th percentile) were associated with significantly poorer performance than low folate or lower homocysteine levels alone.
Recent research shows an association with folate levels and mild cognitive impairment (MCI) and some forms of dementia. Quadri and colleagues [34 . ] performed direct comparisons between serum folate and incidence of MCI, and Alzheimer's disease, and vascular dementia. They found that people with the lowest serum levels of folate were at greater risk for MCI and dementia. In the same study, elevated homocysteine was associated with dementia, but not with MCI. Mizrahi and coworkers [35] found that Alzheimer's patients consumed less dietary folate than controls, but that there was no relationship between either folate intake and homocysteine levels, or homocysteine levels and cognitive status. Engelborghs and colleagues [36 . ] found significant correlations between low RBC folate levels and impairment in Alzheimer's and frontotemporal dementias. Snowdon and coworkers [37] examined atrophy in the neocortex of deceased participants in the Nun Study with Alzheimer's disease and compared these data with serum folate levels that had been determined earlier. They found a negative correlation between folate status and severity of atrophy in participants with a significant number of diseaserelated lesions in the neocortex. This effect was seen even in participants without significant atherosclerosis or brain infarcts, suggesting further that the role of folate is not limited to its relationship with homocysteine, and homocysteine's putative vascular effects. While there is abundant evidence to indicate an association between folate status and the development or progression of cognitive decline or dementia, a causative role is not clear-cut. On the one hand, some data suggest that folate inadequacy precedes onset of cognitive impairment or dementia [34 . ]. On the other hand, there is evidence to suggest that dietary intakes of folate are lower in people with Alzheimer's disease [35] . Therefore, as is the case with depression, it is difficult to determine whether decreased folate status is causal, the product of, or simply concomitant with certain aspects of cognitive decline.
Supplementation with B vitamins, including folic acid, can decrease homocysteine levels [38,39 . . ] and produce changes in cognitive performance [21, 40, 41] , but these changes are not clear-cut. Bryan and colleagues [21] provided women with 750 mg folate for 35 days, and conducted cognitive and mood tests before and following supplementation. They found that folate significantly improved performance in a speed-of-processing task for women with initially lower folate levels. In younger women, they found that folate significantly enhanced recall for those with initially lower folate levels. The effects of folate supplementation, however, were not consistent across the study or across different age groups. Nilsson and colleagues [41] studied vitamin B12 and folic acid supplementation in older patients with mild to moderate dementia. Performance on cognitive tasks was measured before and after 2 months of supplementation with 5 mg/day folic acid and 1 mg/ day cyanocobalamin. They found that in patients with elevated homocysteine, vitamin supplementation decreased homocysteine levels and patients improved on measures of attention, memory and orientation. In contrast, Sommer and colleagues [40] examined 10 mg twice daily (20 mg/day) folic acid supplementation for 10 weeks in patients with dementia, and reported that those in the folic acid condition performed worse relative to controls on some tasks and that there were no group differences for other tasks. There are several considerations in interpreting the findings on vitamin supplemen-tation and cognition. First, there is no standard dose of folic acid that is recommended for this type of trial, although doses of 0.8 mg/day of folic acid over several months is sufficient to produce significant reductions in serum homocysteine [42] . Doses above 1.0 mg/day are generally considered pharmacologic doses rather than nutritive doses [43 . ] and some possible risks of highdose supplementation will be discussed below. Coupled with a lack of standard dosing is the fact that the cutoff for low serum or RBC folate can also be somewhat arbitrary -and in some cases may not be empirically measured through blood chemistry but through dietary assessment alone. Additionally, in people with dementia or other cognitive impairment, the severity of impairment alone is of importance. For example, Nilsson and colleagues excluded severely demented patients from their study because the patients were unable to complete testing either before or after supplementation. Finally, the relationship between folate status and homocysteine as a pathogenic mechanism should be considered. Again, in the Nilsson study, patients with elevated homocysteine showed cognitive improvements following vitamin supplementation, whereas those with normal levels of homocysteine, but who did have mild to moderate dementia, did not. As a correlative, the ability of vitamin supplementation to offset existing cognitive decline is somewhat dependent upon the duration of cognitive decline [44] .
Are there health consequences of too much folate?
Since 1998, bread and cereal products in the US have been fortified with folic acid, the motivating force being reduction of neural tube defects. However, the widespread fortification of folic acid and increasing use of supplements and use of other fortified foods (e.g. fortified orange juice and 'complete nutrition'-type cereals) leads to the question of whether there are negative consequences of too much folate.
The most commonly cited risk of folic acid is the potential to exacerbate the neurological consequences of a vitamin B12 deficiency -directly or by delaying diagnosis. The evidence for this concern reaches back to the initial synthesis of folic acid and its initial application -to treat pernicious anemia. Folic acid was identified and synthesized 3 years prior to the identification of the role of B12. The resulting treatment with folic acid resulted in improvements in anemia, but appeared to promote neurological problems (see [43 . ,45] ). Folic acid may also have negative, excitatory effects in some epileptic patients [43 . ]. Other argued risks include drug interactions and interference with zinc utilization, but these risks have not been substantiated [46] . A safe upper limit of 1.0 mg/day folate from all sources might resolve possible negative interactions with vitamin B12 [47] . In many of the studies cited throughout this review, the researchers report that participants showed no ill effects of folic acid supplementation. Benefits of folic acid supplementation appear to include reduced risk for vascular disease and some forms of cancer [48] , and improvements in mood and in some forms of cognitive decline.
Conclusion
The current available evidence on the associations between folate and mood and cognitive disorders suggests that we have only begun to unravel the nature of the relationship. As outlined above, the role of folate is not clear-cut in these disorders, but there remains a compelling commonality to many of the research studies. Folate, perhaps through its role in homocysteine or neurotransmitter metabolism, may be predictive of treatment outcome in depression, may offset cognitive decline, and may play a role in the disease pathology of Alzheimer's. However, not all findings with respect to folate support a posited role of folate in these disorders. Some studies fail to find a relationship between folate and brain functioning, and at least one study reports a worsening of performance after folic acid supplementation. Clearly, the relationship between nutrition and brain functioning is quite complex, and methodology is an important factor in addressing this relationship. Future research aimed at determining optimal levels of folate -both in a healthy and in a disease state -as well as determining critical time points for folate's actions in these conditions will greatly enhance our understanding of folate and brain function.
